Statement of Principles concerning renal artery atherosclerotic disease (Reasonable Hypothesis) (No. 56 of 2020)

The instrument centrally concerns two linked legal-medical concepts: (1) the statutory definition for the condition being claimed, and (2) the threshold of factors that will, if present, satisfy the minimum necessary to raise a reasonable hypothesis that the condition is connected to relevant service.

Definition of the condition. Section 7(2) supplies the operative definition of “renal artery atherosclerotic disease” for claims: it must be atherosclerosis of the renal arteries causing partial or complete occlusion and either warrant medical treatment or manifest as one of five listed clinical outcomes (moderate to severe hypertension; poorly controlled hypertension; persistent renal impairment; acute pulmonary oedema; chronic heart failure). The instrument explicitly displaces a purely code-driven approach: although the disease maps to ICD‑10‑AM code I70.1, subsection 7(3) instructs that the meaning for the Statement is the text in subsection 7(2), with the ICD code referenced only as an identifier (s7(3)-(4)).

Death is part of the scope. Section 7(5) extends the condition to include “death from” the disease where the disease contributed to a terminal event or condition. The Schedule defines “terminal event,” enumerating outcomes such as pneumonia and cardiac arrest, so death claims are covered where those terminal events were contributed to by the disease.

Factors and thresholds. Section 9 provides a closed list of factors (numbered 1-32) any one of which, as a minimum, must be shown to raise the reasonable hypothesis. The factors fall into groups: classical atherosclerotic risk factors (hypertension, diabetes mellitus, dyslipidaemia, obesity, smoking or second‑hand smoke exposure), metabolic or inflammatory conditions (hyperhomocysteinaemia, periodontitis), renal-specific conditions (chronic kidney disease, abnormal kidney structure or function), lifestyle and functional measures (inability to undertake >3 METs activity, fruit and vegetable consumption below 100 g/day for sustained periods), radiation exposure (therapeutic radiation involving the renal artery or cumulative equivalent dose ≥0.5 sievert), medication proximate to clinical worsening (ACE inhibitor or ARB within 3 months), and a residual category of inability to obtain appropriate clinical management (s9(1)-(32)).

Temporal distinctions. The instrument separates factors that establish a link to clinical onset from factors that establish material contribution or aggravation (s10). For onset, factors are largely in s9(1)-(15). For material contribution or aggravation where the disease pre-existed or was contracted before/during service, the instrument restricts application to factors listed in s9(16)-(32) (s10(2)). Several factors include explicit timing windows , for example, obesity must have been present for at least five years within the 20 years prior to clinical onset (s9(3)), and smoking cessation windows affect the required pack-year thresholds (s9(5)-(6)).

Definitions and measurement standards. Schedule 1 supplies measurement rules: “being obese” is BMI ≥30 and BMI is defined as W/H2 (Schedule 1). “One pack-year” is quantified and an example is given, with a 7,300-gram tobacco equivalence for non-cigarette products and a calculation example (Schedule 1). “Cumulative equivalent dose” must be calculated per the ARPANSA Guide to calculation as in force on 2 August 2017 (Schedule 1), and the definition expressly excludes normal background radiation (Schedule 1). Dyslipidaemia is defined with explicit laboratory thresholds for HDL, LDL, triglycerides and total cholesterol or the regular administration of lipid-lowering therapy (Schedule 1). Chronic kidney disease is defined as an abnormality of kidney structure or function present for at least three months (Schedule 1), and “abnormality of kidney structure or function” is itself defined in terms of GFR <60 mL/min/1.73 m2, imaging, biopsy, albuminuria, urinary sediment abnormalities or kidney transplant (Schedule 1).

Administrative basis and limits. Section 8 records that the Repatriation Medical Authority regards there to be “sound medical‑scientific evidence” linking the disease and death from it to service. The instrument is therefore a conclusion by the Authority, expressed as a Statement of Principles, for use in statutory claim processes. It does not set out how decision-makers must weigh competing evidence, nor does it amend rights or liabilities outside the claim context; those practical adjudication mechanics sit within the VEA/MRCA decision frameworks, to which the instrument applies under section 5.

Cross-references. If a listed factor itself refers to another injury or disease covered by a different Statement of Principles, that other Statement applies “in accordance with the terms of that Statement” (s11). This creates an interplay where evidence that invokes another Statement requires using that Statement’s criteria as well.

Primary affected persons. The instrument applies to claims that fall under section 120A of the VEA or section 338 of the MRCA (s5). It therefore directly affects persons asserting that renal artery atherosclerotic disease, or death from that disease, is connected to “relevant service.” The Schedule’s definition of “relevant service” enumerates operational, peacekeeping, hazardous, British nuclear test defence service under the VEA and warlike and non-warlike service under the MRCA (Schedule 1). In practice the primary affected cohort is veterans and certain serving or former members who have those forms of service.

Decision-makers and agencies. The instrument is produced by the Repatriation Medical Authority under s196B(2) VEA (s3 and s8). Its intended use is by administrative decision-makers who adjudicate VEA and MRCA claims , principally staff of the Department responsible for veterans’ entitlements and the Repatriation Commission , because section 5 says the instrument “applies to a claim” under the specified Act sections. The instrument therefore affects medical adjudicators, case officers, medical reviewers, and the Repatriation Medical Authority itself as the source of the medical criteria.

Treating clinicians and expert witnesses. The instrument affects clinicians who provide nexus opinions or reports. The listed factors are granular and measurable , for example laboratory thresholds for dyslipidaemia and a defined BMI calculation , so clinicians supplying supporting evidence will be called on to document dates, laboratory values, imaging, treatment courses, and functional limitation assessments in terms that correspond to the instrument’s definitions (Schedule 1; s9).

Claim preparation and legal/advocacy professionals. Lawyers, advocates, and allied health professionals preparing claims will be affected because the instrument sets the minimum evidential thresholds that must be addressed. For example, where the claimant relies on radiation exposure, the Schedule requires cumulative equivalent dose calculation per the ARPANSA Guide as in force on 2 August 2017, so claim preparers must obtain dose reconstructions or records that can be converted into that metric (Schedule 1).

Indirectly affected parties. Employers, military units, and third parties who can provide corroborating evidence (rosters, smoking policies, occupational exposure histories, deployment records, dental records) will find their records relevant. The instrument’s second‑hand smoke thresholds (1,000 and 5,000 hours) require quantified exposure histories, which can implicate workplace records or witness statements (s9(7)-(8) and Schedule 1 definition of being exposed to second-hand smoke).

Who does not get affected rights or obligations from this instrument. The instrument does not itself create new entitlements or new criminal sanctions. It does not determine the outcome of a claim; it supplies criteria that, if met, raise a reasonable hypothesis connecting disease to service. Whether a claim succeeds depends on subsequent statutory adjudication processes under the VEA/MRCA, and any appeals or review routes provided by those statutes. The instrument therefore affects administrative decision-making thresholds but does not itself, on its face, change substantive entitlements beyond being the evidentiary foundation for adjudication.

Statutory applicability. The instrument “applies to a claim to which section 120A of the VEA or section 338 of the MRCA applies” (s5). That textual formulation makes the instrument a prescribed source of principles to be applied in claim assessment. The key operational consequence is that where a relevant claim is before a statutory decision-maker, the instrument’s factors are the enumerated minimum criteria for raising a reasonable hypothesis that the disease is connected to service (s9 opening).

Duty to consider factors. The instrument itself does not create express procedural duties such as timeframes or mandatory steps for decision-makers; however, by operation of s5 and its status as a Statement of Principles issued under s196B(2) VEA, the instrument functions as the medical criteria decision-makers should follow in assessing causation for applications under the specified sections. Practically, decision-makers will be expected to ascertain whether at least one of the factors in s9 is present and related to the person’s relevant service (s9; s10(1)). That creates an implied administrative duty to evaluate the presence or absence of each potentially relevant factor and its relationship to service.

Claimant evidential task. The instrument sets an evidential floor for claimants and their medical supporters: at least one factor in s9 must be shown to exist before it “can be said that a reasonable hypothesis has been raised” connecting the disease to service (s9). Claimants therefore have the practical duty to marshal evidence that maps to one or more of the specific factors and to date the clinical onset or clinical worsening against the temporal windows in the instrument.

Right to have claims judged against the instrument. Section 5 gives rise to a right in the sense that claims falling under the cited statutory sections will be governed by the instrument. That means claimants can expect adjudicators to apply these exact criteria when assessing whether a reasonable hypothesis exists. If a factor referred to in s9 is an injury or disease covered by another Statement of Principles, s11 makes those other Statements applicable “in accordance with the terms of that Statement as in force from time to time,” so claimants and decision-makers have a right to consult and rely on those other Statements where referenced.

Medical assessment standards. The Schedule provides measurable thresholds (for example dyslipidaemia numerical cut-offs, BMI calculations, MET definition, cumulative equivalent dose methodology). Those standards function as duties on medical experts and reporting clinicians to present their findings using those metrics where relevant. A clinician who does not report, for example, LDL, HDL, triglyceride or total cholesterol values when dyslipidaemia is invoked will leave a gap in the evidentiary chain because the instrument requires those thresholds to be met (Schedule 1).

Limits and undefined duties. The instrument includes factors such as “inability to obtain appropriate clinical management for renal artery atherosclerotic disease” (s9(32)) but does not define “appropriate clinical management” or set procedural steps for establishing inability to obtain it. That creates an evidentiary ambiguity that allocates to decision-makers and medical assessors the task of interpreting what proof will suffice. Similarly, the instrument does not prescribe how to apportion weight among multiple factors nor how to treat competing evidence as between pre-service and post-service exposures; those adjudicative tasks remain within the VEA/MRCA decision processes.

No penalties or enforcement provisions within the instrument. The instrument contains no criminal or civil penalties, nor does it contain explicit enforcement mechanisms beyond its application to claims (see s3, s5). The legal “right” and “duty” architecture is therefore administrative and evidentiary rather than coercive.

The instrument does not create offences, civil sanctions, or penalty regimes. Nowhere in the text is any criminal penalty or monetary fine specified; the instrument is a Statement of Principles made under subsection 196B(2) of the VEA and, through section 5, is applied to claims under particular statutory sections (s3; s5). Its operative function is evidentiary: it lists the factors that, if present, constitute the minimum necessary to say that a reasonable hypothesis connecting renal artery atherosclerotic disease to relevant service has been raised (s9).

Enforcement in practice is administrative and procedural rather than penal. The instrument will be applied by the administrative decision-makers and clinical assessors responsible for considering claims under the VEA and MRCA. These decision-makers will use the instrument’s factors when forming an opinion about whether the required threshold of causal connection is established for the purposes of claim adjudication. Any enforcement in the sense of claim acceptance or rejection therefore follows the adjudicative channels and remedies under the VEA and MRCA rather than via this instrument itself.

Remedies and review processes are not set out in this instrument. The instrument is silent on appeal, review, or remedy mechanisms; those are governed by the procedural and merits review provisions of the VEA and MRCA. Because the instrument does not prescribe enforcement actions, the relevant practical consequence for claimants is that failure to meet the instrument’s criteria will tend to result in an administrative finding that a reasonable hypothesis has not been raised, which in turn will influence claim outcomes and any subsequent review avenues that the underlying statutes provide.

Administrative compliance and investigatory tasks. In the absence of penalty provisions, the principal “enforcement” is the administrative requirement to produce or obtain medically admissible evidence matching the instrument’s measures. For example, to establish a radiation factor a claimant must rely on dose calculation by the methodology specified in the Schedule (cumulative equivalent dose calculated according to the ARPANSA guide as in force on 2 August 2017) (Schedule 1). The practical enforcement therefore lies in the obligation on decision-makers to verify that evidence meets the instrument’s technical standards.

Record-keeping and accuracy implications. Because the instrument specifies objective thresholds (for example dyslipidaemia lab cut-offs, BMI formulas, pack-year calculations and second-hand smoke hours), inaccurate or incomplete records will tend to result in an inability to establish the required factor. There is no express mechanism in the instrument to admit less direct evidence where primary data are missing; such evidentiary questions are resolved within the VEA/MRCA decision-making processes that apply the instrument.

Direct statutory linkage. The instrument is made under subsection 196B(2) of the VEA (s3) and applies to claims under section 120A of the VEA and section 338 of the MRCA (s5). Those statutory linkages mean the instrument is an embedded source of medical policy within the broader statutory framework for veterans’ entitlements and military compensation. The instrument therefore operates as a specialised evidentiary annex to the VEA/MRCA causation inquiry.

Interaction with other Statements of Principles. Section 11 provides a clear cross-reference mechanism: if a factor listed in section 9 refers to an injury or disease covered by another Statement of Principles determined under subsection 196B(2) VEA, then the factors in that other Statement “apply in accordance with the terms of that Statement as in force from time to time” (s11). The practical effect is hierarchical: where a factor invokes another instrument, decision-makers and claimants must consult both this instrument and the other Statement, and apply the other Statement’s specific terms for the referenced condition.

Use of external medical standards and instruments. The instrument refers to external sources and technical guides, which creates cross-legal and inter-agency dependencies. For radiation exposure, “cumulative equivalent dose” is to be calculated in accordance with the ARPANSA Guide to calculation as in force on 2 August 2017 (Schedule 1). ICD‑10‑AM is used as an identifier for the disease (s7(3)-(4)), with the specific edition and effective date cited. Those references mean that changes to those external technical instruments may affect how evidence is prepared and assessed; the instrument fixes a particular edition or version for the purposes of the calculation it prescribes.

Compatibility with diagnostic coding. Section 7(3) clarifies that although renal artery atherosclerotic disease attracts ICD‑10‑AM code I70.1, the Statement’s operative definition is the textual one in s7(2). This prevents an automatic equivalence between an ICD code in a record and the acceptance of the claim; adjudicators must apply the instrument’s textual criteria and not rely solely on ICD coding.

Overlap with general medical law and professional obligations. Clinicians preparing reports for claims will be operating within their professional regulatory frameworks (clinical standards, privacy law, informed consent, medical records obligations). The instrument’s definitions and thresholds (for example dyslipidaemia cut-offs; BMI calculations) should be used by clinicians when preparing evidence, consistent with their clinical duties. The instrument does not alter clinicians’ legal duties but establishes how the clinical evidence will be assessed in the claims context.

Effect on evidentiary law. The instrument sets admissibility-relevant thresholds by specifying what evidence is necessary to raise the reasonable hypothesis. Evidence that matches these thresholds will have probative force in the administrative claim process. The instrument does not change the rules of judicial evidence in courts, but it shapes the administrative evidentiary expectations and, through the VEA/MRCA, may be consequential on merits review or judicial review proceedings in which the administrative decision-makers’ use of the instrument is contested.

Interplay with amendments and legislative instruments. The endnotes identify amendment determinations (Endnote 3 and 4): for example, the Veterans’ Entitlements (Statements of Principles,definition of "one pack-year") Amendment Determination 2022 (No. 94 of 2022) amended the definition of one pack-year and related notes. Those amending instruments, and the Legislation Act 2003 entries referenced in the amendment history, indicate that the Statement is part of a body of legislative instruments subject to amendment and compilation. Practitioners must consult the current in-force version and the cited endnotes to confirm which definitions apply to a particular claim.

No conflict with criminal or public health law. The instrument does not interact with criminal sanctions or public health regulation directly. It uses public health concepts (smoking, radiation exposure, obesity) but its function is limited to assessing causal connection for claims under veterans’ compensation statutes.

The compilation header and endnotes supply the amendment history relevant to this instrument. The Statement was first made and registered as the Statement of Principles concerning renal artery atherosclerotic disease (No. 56 of 2020), registered 31 August 2020 and commencing on 28 September 2020 (Endnote 3: legislation history). The compilation includes amendments up to the Veterans’ Entitlements (Statements of Principles,definition of "one pack-year") Amendment Determination 2022 (No. 94 of 2022), which was registered on 26 August 2022 and commenced on 19 September 2022; the compilation date is 19 September 2022.

Endnote 4 lists specific provision-level amendment notations. The amendment history table in the endnotes records that notes to subsections 9(5), 9(6), 9(20) and 9(21) were revised by the 2022 amendment, and that the Schedule 1 definition of “one pack-year” was revised by that instrument. The endnotes also indicate republished entries in the compilation noting repeals under the Legislation Act (for example entries for Section 2 and Section 4 show “rep LA s 48D” and “rep LA s 48C”), which reflect the mechanics of how the compilation is prepared and annotated under the Legislation Act 2003; these compilation annotations should be read as editorial markers rather than substantive changes to the Statement’s operative content.

The Schedule continues to reference external instruments as in force on particular dates, for example the ARPANSA guide “as in force on 2 August 2017” for cumulative equivalent dose calculation (Schedule 1). Those fixed-date references indicate that the instrument ties certain technical definitions to particular external versions rather than allowing unbounded incorporation of later versions, unless the Schedule or a subsequent amending instrument changes the referenced version.

Practitioners and claimants should consult the Legislation Register for any post-compilation amendments or uncommenced amendments; the compilation itself notes that uncommenced amendments are not shown in the text and points readers to the Legislation Register for the latest instrument versions (compilation header notes). The amendment history confirms that the instrument has been subject to at least one targeted amendment (the pack-year definition), and the endnotes track which subsections were affected.

The text of this instrument, and the endnotes supplied in the compilation, contain no citations to judicial or tribunal decisions. The endnotes set out only the legislative instrument registration and amendment history; they do not record litigation or appellate outcomes. Therefore, based on the supplied instrument text and its endnotes, there is no litigation history embedded in the Statement of Principles itself.

What that absence means for practitioners. The lack of litigation history in the instrument does not indicate that disputes will not arise about its application in particular claims; it only means that the instrument’s compilation does not include case law. Legal challenges to administrative decisions that apply this instrument would be litigated under the VEA/MRCA statutory review and merits review processes or by judicial review in the courts. Any such cases would need to be located through case law research databases and tribunal records rather than in the Statement’s endnotes.

Points that litigants are likely to contest. Although not drawn from court reports, the instrument contains several aspects that could be points of contention in disputes: the strictness of temporal windows (for example five years within 20 years, or 20-year post-cessation smoking windows), the quantification of second-hand smoke exposure by hours, the use of a specific ARPANSA guide version for radiation dose reconstruction, the treatment of pre-existing renal artery atherosclerotic disease and the limited application of factors 9(16)-(32) to cases of material contribution or aggravation, and the undefined notion of “inability to obtain appropriate clinical management” in s9(32). Any judicial scrutiny of administrative decisions is likely to focus on whether decision-makers correctly applied the instrument’s definitions, adhered to the required temporal linkages in s10, and respected cross-references to other Statements under s11.

Records to seek in potential litigation. If a decision is challenged, source documents that will be central include medical records establishing clinical onset and worsening dates, laboratory results matching dyslipidaemia thresholds, BMI/calculated BMI history, smoking histories with dates and pack-year calculations, workplace/deployment records for second-hand smoke exposure quantification, dental records for periodontitis duration, dose reconstructions or radiotherapy records tied to ARPANSA methodology, prescription records showing ACE inhibitor or ARB use within the 3-month window, and any records demonstrating inability to obtain appropriate clinical management. The Schedule supplies explicit measurement metrics that any litigant will need to correlate with documentary proof.

Because there is no litigation history in the instrument text, practitioners should treat the instrument as an administratively authoritative Statement that will be applied by decision-makers and prepare to contest any misapplication through the statutory review routes in the underlying Acts.

Precise measurement requirements. Many factors are expressed in precise, numerically quantifiable terms: BMI ≥30 (Schedule 1); dyslipidaemia cut-offs (Schedule 1); one pack-year as 20 cigarettes/day for a year or the 7,300 grams tobacco equivalence for other tobacco types (Schedule 1); second-hand smoke exposure thresholds measured in hours (s9(7)-(8) and Schedule 1); inability to undertake activity greater than three METs (s9(10), s9(25) and Schedule 1). A common “gotcha” is failing to present evidence that matches these metrics. For example, a clinic note stating “long-term smoker” without a pack-year calculation will not align with the instrument’s pack-year thresholds.

Temporal windows and differing durations. Several factors require sustained exposure or duration within specified windows. Obesity must have persisted for at least five years within the 20 years before clinical onset or clinical worsening (s9(3), s9(18)). Smoking cessation changes the pack-year requirement depending on whether cessation was permanent and when clinical onset/worsening occurred (s9(5)-(6), s9(20)-(21)). Second-hand smoke exposure has a 1,000-hour trigger where exposure has not permanently ceased, but where exposure has ceased, a 5,000-hour threshold or a 1,000-5,000 hour band with a five-year recency window applies (s9(7)-(8), s9(22)-(23)). Practitioners must map exposure dates precisely to the clinical onset or worsening dates claimed; sloppy chronology is likely to fail the instrument’s test.

Onset versus aggravation distinction. Section 10 draws a critical distinction: factors in s9(16)-(32) apply only to material contribution to, or aggravation of, the disease where the disease was “suffered or contracted before or during (but did not arise out of) the person's relevant service” (s10(2)). That means if the disease arose as a result of service, the s9(16)-(32) factors are not the correct path for showing material contribution. Misapplying those factors without establishing the pre-existence of the disease before or during service will be a procedural error.

Chronic kidney disease duration versus definition. Schedule 1 defines chronic kidney disease as an abnormality of kidney structure or function present for at least three months. However, the factors in s9(11) and s9(26) require “having chronic kidney disease for a period of at least five years before the clinical onset” or before clinical worsening. Practitioners must reconcile the two: the Schedule sets the medical definition while the factor requires a longer duration for causation purposes. Showing three months of CKD is not sufficient for s9(11) or s9(26); five years’ duration is required by the factor.

Radiation dose measurement intricacies. The instrument requires a cumulative equivalent dose of at least 0.5 sievert to the renal artery (s9(13), s9(28)), calculated per the ARPANSA guide in force on 2 August 2017 (Schedule 1). Dose reconstruction is technical, may require specialised expertise, and excludes background radiation. A typical problem is reliance on non-conforming dose metrics or on facility-level exposure notes that cannot be converted into the ARPANSA-specified cumulative equivalent dose without further modelling.

Dietary and functional evidence difficulties. The instrument requires evidence that a person was unable to consume an average of at least 100 grams per day of any combination of fruit and vegetables for at least five consecutive years within the 20 years before onset or worsening (s9(14), s9(29)). Providing reliable, contemporaneous diet documentation for a five-year stretch is challenging. Similarly, proving an inability to undertake physical activity greater than three METs for at least five years within 20 years requires functional assessments, occupational records, or ongoing clinical notes; ad hoc statements are unlikely to satisfy the instrument.

ACE inhibitor/ARB timing narrowness. Factor 31 requires treatment with an ACE inhibitor or angiotensin receptor blocker within the three months before clinical worsening (s9(31)). The three-month window is narrow and requires clear prescription or dispensing records tied to the documented date of clinical worsening.

“Inability to obtain appropriate clinical management” is undefined. Factor 32 lacks a definitional anchor in the Schedule. That creates evidentiary ambiguity: claimants and clinicians must supply persuasive materials demonstrating system-level barriers or individual inability to access appropriate care. The instrument offers no prescriptive checklist for what will suffice, and decision-makers will have discretion in evaluating the adequacy of proof.

Cross-referencing to other Statements of Principles. Where a factor invokes another Statement (s11), practitioners must identify and apply that other Statement’s terms. Failure to do so , for example, citing a factor that refers to chronic kidney disease without checking the CKD Statement where relevant , will leave a lacuna in the evidentiary chain.

ICD-10-AM code not dispositive. Because s7(3) specifies that the operative meaning is the textual definition, reliance solely on an ICD-10 code in a discharge summary or bill is insufficient. The clinician’s report must demonstrate that the disease meets the s7(2) criteria (occlusion and either medical treatment warranted or one of the listed manifestations).

Document chronology precisely. Establish and document dates for service, clinical onset, and any clinical worsening. Section 9’s factors hinge on duration and timing relative to clinical onset or clinical worsening; for example many factors require periods of five years within a 20-year window, or cessation windows of up to 20 years for smoking (s9(3), s9(6), s9(18), s9(21)). A chronological timeline cross-referencing medical records, deployment histories, and prescription or dental records is essential.

Map evidence to specific factors and Schedule definitions. For each invoked factor, assemble documentary proof that aligns with the instrument’s definitions in Schedule 1. Examples:

• Dyslipidaemia: provide serum HDL, LDL, triglyceride and total cholesterol laboratory results and, if relevant, records showing regular lipid-lowering drug therapy (Schedule 1 dyslipidaemia definition).
• BMI/obesity: produce weight and height records to calculate BMI per Schedule 1; demonstrate persistence for the required five-year period where s9(3) or s9(18) is relied on.
• Smoking: prepare a pack-year calculation according to the Schedule definition and include dates of cessation, if any, to apply s9(5)-(6), s9(20)-(21).
• Second-hand smoke: collect witness statements, employment records, or location logs to quantify hours of exposure, noting the 1,000 and 5,000 hour thresholds and recency rules (s9(7)-(8), s9(22)-(23)).
• Chronic kidney disease: produce GFR values, imaging, biopsy reports, albuminuria traces or transplant records to meet the Schedule’s “abnormality” definition; additionally document duration for five-year factors.
• Radiation: obtain radiation treatment plans, dosimetry data and any service records related to nuclear testing or aircrew exposure, then commission a dose reconstruction calculated per the ARPANSA guide as specified in the Schedule to demonstrate cumulative equivalent dose (Schedule 1; s9(12)-(13), s9(27)-(28)).

Use clinicians who will report in the instrument’s terms. Request that treating clinicians and medical experts structure their reports explicitly around the instrument’s factors and Schedule definitions. For example, ask clinicians to state whether the patient’s hypertension has been “for a period of at least five years” and to give dates, or to state whether the patient’s LDL is greater than 4.0 mmol/L and cite lab dates and values (s9(1), Schedule 1 dyslipidaemia). For functional evidence, obtain formal functional capacity assessments that record METs performance where s9(10) or s9(25) are invoked.

For diet and periodontitis items use contemporaneous or specialist records. Diet requires an average intake calculation over extended periods; where contemporaneous food diaries are absent, use corroborative evidence such as specialist nutrition notes, GP dietary counselling records, or evidence of food insecurity/medical conditions preventing adequate intake (s9(14), s9(29)). For periodontitis, obtain dental records demonstrating diagnosis and duration of disease for at least two years before onset or worsening (s9(15), s9(30)).

Document inability to obtain appropriate clinical management carefully. Factor 32 is open-text; collect evidence such as referral denials, waitlist documents, geography-driven lack of services, financial inability to access recommended care, or military-era barriers. Where possible, document contemporaneous attempts to obtain care and provide corroboration (appointments scheduled but unavailable, correspondence with providers).

Address pre-existence and aggravation rules. If relying on factors in s9(16)-(32) to show material contribution or aggravation, demonstrate that the disease was “suffered or contracted before or during (but did not arise out of) the person’s relevant service” per s10(2). That requires establishing the disease pre-existed service or was present during service but not caused by it. Provide medical records predating service or from during-service medical examinations to show pre-existence.

Check for references to other Statements of Principles. If a factor refers to another Statement, obtain and apply that Statement in full in support of the claim as required by s11. For instance, if a factor invokes chronic kidney disease and a separate Statement addresses CKD causation, include an analysis mapped to both Statements.

Use ARPANSA-conforming dose reconstructions for radiation. For radiation-related factors, obtain a dose assessment that follows the ARPANSA Guide specified in the Schedule. Ensure that the reconstruction excludes background radiation as required and that it quantifies cumulative equivalent dose to the renal artery specifically (Schedule 1).

Prepare for narrow medication windows. If the claim invokes ACE inhibitor or ARB treatment under s9(31), obtain precise prescription or dispensing dates showing treatment within three months before clinical worsening. Pharmacy dispensing records and medical notes will be necessary.

Cross-validate ICD coding with textual criteria. Do not rely solely on ICD-10-AM coding. While the instrument notes the disease maps to I70.1 (s7(3)), the textual criteria in s7(2) govern the instrument’s scope. Therefore ensure charting and imaging reports explicitly describe occlusion and one of the listed clinical manifestations.

Keep service records and corroborative administrative documents. Because the instrument applies only to claims tied to “relevant service” (Schedule 1), collect service records establishing the type of service (operational, peacekeeping, hazardous, nuclear test, warlike, non-warlike). For second-hand smoke and other occupational exposure claims, obtain unit logs, billets records, or contemporaneous complaints that quantify exposure.

Anticipate missing data and plan alternatives. In many older cases contemporaneous diet or exposure logs will be absent. Prepare alternative corroborative material: affidavits from family or co-workers, depletion-of-resources documentation, treatment notes showing progressive decline consistent with the claimed factor, and, where necessary, expert opinion that links available evidence to the instrument’s criteria.

Consult the most recent versions and endnotes. The compilation notes that the instrument has been amended (for example the 2022 amendment addressing the definition of one pack-year). Ensure that practitioners rely on the in-force text and the Legislation Register for any further amendments beyond the compilation date.

File evidence in a format that decision-makers can apply directly. Structure claim bundles so each piece of evidence is annotated to the exact clause or Schedule definition it is intended to support. That reduces the risk of administrative error or misinterpretation and aligns with the instrument’s function as a checklist of factors that, if present, raise a reasonable hypothesis (s9).